Viridian Therapeutics

VRDN · NASDAQ

$22.43+$1.63 (+7.84%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $20.80

Latest news

Press releaseOct 20, 4:00 PM ETBusiness Wire
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
NewsOct 16, 10:12 AM ETVandana Singh
Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy
NewsSep 3, 12:19 PM ETTim Melvin
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
Press releaseAug 6, 7:01 AM ETBusiness Wire
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Press releaseJun 29, 9:50 AM ETGlobe Newswire
4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones
NewsJun 29, 9:24 AM ETVandana Singh
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
NewsJun 29, 8:52 AM ETRishabh Mishra
Stock Market Today: Nasdaq, Dow S&P 500 Futures Jump As Trump Admin Says US, Iran Will 'Stand Down' For Now— Verizon, HP, Universe Pharmaceuticals In Focus (UPDATED)
NewsJun 29, 2:34 AM ETAvi Kapoor
Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday
Press releaseJun 26, 6:00 PM ETBusiness Wire
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Press releaseMay 27, 7:00 AM ETBusiness Wire
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Press releaseMay 6, 11:13 PM ETBusiness Wire
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Press releaseMay 5, 4:05 PM ETBusiness Wire
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
NewsMay 5, 1:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsMay 5, 8:06 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseMay 5, 7:01 AM ETBusiness Wire
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Press releaseMay 5, 7:00 AM ETBusiness Wire
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
NewsApr 6, 1:41 PM ETVandana Singh
Why Is Viridian Therapeutics Stock Sinking Monday?
NewsMar 30, 1:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsMar 30, 12:02 PM ETAvi Kapoor
Crude Oil Rises Over 2%; US Dallas Fed Manufacturing Index Declines In March
NewsMar 30, 10:25 AM ETAvi Kapoor
Dow Gains 200 Points; Bullfrog AI Shares Jump
NewsMar 30, 8:05 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
Press releaseMar 30, 7:01 AM ETBusiness Wire
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
NewsFeb 26, 7:24 AM ET
Earnings Breakdown: Viridian Therapeutics Q4
Press releaseFeb 26, 7:01 AM ETBusiness Wire
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Press releaseJan 8, 4:01 PM ETBusiness Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJan 6, 7:01 AM ETBusiness Wire
Viridian Therapeutics Prepares for Transformational 2026
NewsDec 31, 10:01 AM ETNamrata Sen
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?
Press releaseDec 22, 7:00 AM ETBusiness Wire
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
NewsDec 15, 10:25 AM ETVandana Singh
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
Press releaseDec 5, 7:00 AM ETBusiness Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseNov 7, 7:00 AM ETBusiness Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseNov 5, 7:01 AM ETBusiness Wire
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Press releaseNov 3, 7:01 AM ETBusiness Wire
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
Press releaseOct 21, 11:24 PM ETBusiness Wire
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
NewsOct 21, 4:00 PM ET
Expert Outlook: Viridian Therapeutics Through The Eyes Of 6 Analysts
NewsAug 7, 2:37 PM ETAvi Kapoor
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy

Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

Stock Market Today: Nasdaq, Dow S&P 500 Futures Jump As Trump Admin Says US, Iran Will 'Stand Down' For Now— Verizon, HP, Universe Pharmaceuticals In Focus (UPDATED)

Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

Why Is Viridian Therapeutics Stock Sinking Monday?

12 Health Care Stocks Moving In Monday's Intraday Session

Crude Oil Rises Over 2%; US Dallas Fed Manufacturing Index Declines In March

Dow Gains 200 Points; Bullfrog AI Shares Jump

12 Health Care Stocks Moving In Monday's Pre-Market Session

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

Earnings Breakdown: Viridian Therapeutics Q4

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Prepares for Transformational 2026

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Expert Outlook: Viridian Therapeutics Through The Eyes Of 6 Analysts

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results